With ProteinPaint, investigators can visualize sequence mutations, gene fusions, and RNA expression to interpret patterns in germline and tumor samples.
The two entities also plan to work together using the data generated from the tests to do added research.
The firm has billed commercial insurers for more than 17,000 tests and reported test results for more than 15,000 Medicare patients without receiving payment.
While the overall number of oncologists who ordered the company's tests in the third quarter did not change, the frequency with which they reordered fell by about 7 percent.
For the second quarter in a row, the company lowered its clinical test volume guidance for 2015 to between 32,000 and 33,000 tests.
The Cologne, Germany-based cancer diagnostics firm plans to use the funds raised to develop a liquid biopsy for its NGS-based NEO platform.
AmoyDx will develop and commercialize a series of oncology tests that use Illumina NGS technology, including the firm's TruSight Tumor 15 panel.
Under the terms of the agreement, N-of-One will provide clinical interpretation services for samples sequenced on a 50-gene hot-spot solid tumor panel.
CiViC provides a communal forum for capturing and sharing written summaries, drawn from published literature, about the clinical relevance of mutations found in cancer.
Deck: The panels, which cover lung, colon, brain, and thyroid cancer as well as melanoma and gastrointestinal stromal tumors, target newly diagnosed patients.
Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.
The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.
Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.
In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.